Duloxetine Capsule, Delayed Release
Product Images NDC 68788-4128

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-4128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed-release Cap Usp 20mg (Duloxetine 20mg)

The image shows a Duloxetine Delayed-Release Capsule label, USP 20 mg, generic for Cymbalta, manufactured by Ajanta Pharma Limited. The label includes dosage information, storage instructions, and cautionary statements. It is a prescription drug in capsule form, white and blue with imprint DLX20. Labeler is Preferred Pharmaceuticals Inc.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve showing the proportion of patients with relapse over time from randomization in days. Two treatment groups are compared: Duloxetine and Placebo. The graph displays relapse proportions on the y-axis and time in days on the x-axis, indicating differences in relapse rates between Duloxetine and Placebo groups over a period of approximately 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It features two lines: one for placebo and one for Duloxetine 60/120 mg once daily. The graph shows higher patient improvement percentages associated with Duloxetine treatment across different pain improvement levels.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time from randomization to relapse in days. Two treatments are compared: placebo (dashed line) and Duloxetine (solid line). The graph displays lower relapse proportions for Duloxetine compared to placebo throughout the observation period up to about 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The graph compares patient response rates across varying levels of pain improvement, illustrating efficacy differences among the Duloxetine dosing regimens and placebo.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The vertical axis represents the percentage of patients improved, and the horizontal axis represents percent improvement in pain from baseline, ranging from >0 to 100%.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. Each group is represented by a different line, illustrating trends in patient improvement as pain improvement percentage increases.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing trends in patient improvement across different thresholds of pain reduction.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percentage of patients improved. Duloxetine shows higher percentages of improvement across most pain levels compared to placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) comparing placebo and Duloxetine 60/120 mg once daily. The X-axis represents percent improvement in pain, while the Y-axis shows the percentage of patients improved, with Duloxetine consistently showing higher patient improvement across pain levels compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for two groups: Placebo and Duloxetine 60 mg once daily. The graph shows Duloxetine consistently outperforming placebo across increasing pain improvement percentages, with data points marked for both groups and vertical grid lines at intervals of 10% to 100% on the x-axis.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride showing the molecular arrangement including a thiophene ring and a naphthalene moiety with an attached methylamino group and hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.